Royalty Pharma Plc (RPRX) Stock Institutional Trading Activity
Royalty Pharma Plc (RPRX) position changes reported by tracked institutional filers across multiple SEC 13F reporting periods. Based on recent SEC 13F filings (Q3 2025), investors with some of the largest reported share count changes include Dorsey Asset Management, Torray Fund, Sequoia Financial Advisors, Viking Global Investors, and Renaissance Technologies LLC. Explore insights into buying and selling patterns, position changes, and investment conviction levels to understand institutional trading behavior and market dynamics.
Explore more:
- Royalty Pharma Plc (RPRX) stock institutional ownership
- Royalty Pharma Plc (RPRX) stock insider trading activity
- Stock rankings
| Portfolio quarter | Name | Type | Quantity | Remaining | Reported stock balance |
|---|---|---|---|---|---|
| Q4 2022 | Viking Global Investors | Sell | -873,083 | 10,008,511 | $395,536,355 |
| Q3 2022 | Torray Fund | Buy | 12 | 139,024 | $5,586 |
| Q3 2022 | Viking Global Investors | Sell | -1,489,100 | 10,881,594 | $437,222 |
| Q2 2022 | Torray Fund | Buy | 6,942 | 139,012 | $5,844 |
| Q2 2022 | Viking Global Investors | Buy | 1,606,222 | 12,370,694 | $520,064 |
| Q1 2022 | Torray Fund | Sell | -5,871 | 132,070 | $5,145 |
| Q1 2022 | Renaissance Technologies LLC | Sell | -615,200 | 183,900 | $7,165 |
| Q1 2022 | Berkshire Hathaway | Sell | -7,151,896 | 1,496,372 | $58,299 |
| Q1 2022 | Viking Global Investors | Buy | 449,094 | 10,764,472 | $419,384 |
| Q4 2021 | Torray Fund | Buy | 137,941 | 137,941 | $5,497 |
| Q4 2021 | Renaissance Technologies LLC | Buy | 15,500 | 799,100 | $31,844 |
| Q4 2021 | Berkshire Hathaway | Sell | -4,497,634 | 8,648,268 | $344,633 |
| Q4 2021 | Viking Global Investors | Buy | 6,174,870 | 10,315,378 | $411,068 |
| Q3 2021 | Renaissance Technologies LLC | Sell | -45,000 | 783,600 | $28,319 |
| Q3 2021 | Viking Global Investors | Buy | 901,854 | 4,140,508 | $149,638 |
| Q3 2021 | Berkshire Hathaway | Buy | 13,145,902 | 13,145,902 | $475,093 |
| Q2 2021 | Renaissance Technologies LLC | Buy | 828,600 | 828,600 | $33,964 |
| Q2 2021 | Viking Global Investors | Buy | 1,176,901 | 3,238,654 | $132,752 |
| Q1 2021 | Viking Global Investors | Sell | -225,247 | 2,061,753 | $89,934 |
| Q4 2020 | Viking Global Investors | Buy | 338,936 | 2,287,000 | $114,464 |
| Q3 2020 | Viking Global Investors | Sell | -566,921 | 1,948,064 | $81,955 |
| Q2 2020 | Viking Global Investors | Buy | 2,514,985 | 2,514,985 | $122,103 |
Frequently asked questions about RPRX activity
Which institutional owners are buying RPRX?
Institutional owners buying RPRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in RPRX activity?
"Buy" means an investor increased their reported position in RPRX compared to the prior reporting period. This reflects growing exposure to Royalty Pharma Plc (RPRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in RPRX increasing?
Institutional interest in RPRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.